of 38
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
1/38
1
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
2/38
2
2
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. Thesestatements relate to future events or the Company’s future financial performance and involve known and unknown risks,uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of theCompany or its industry to be materially different from those expressed or implied by any forward-looking statements. Insome cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,”“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparableterminology. All statements other than statements of historical fact could be deemed forward-looking, including anyexpectations regarding investment returns; any projections of financial information; any statements about historicalresults that may suggest trends for our business; any statements of the plans, strategies, and objectives of managementfor future operations; any statements of expectation or belief regarding future events, potential markets or market size,or technology developments; and any statements of assumptions underlying any of the items mentioned. The Companyhas based these forward-looking statements on its current expectations, assumptions, estimates and projections. Whilethe Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond theCompany’s control. These and other important factors may cause actual results, performance or achievements to differmaterially from those expressed or implied by these forward-looking statements. These statements may involve risksand uncertainties that could cause actual results to differ materially from the expected results. Such risks include butare not limited to the risk factors set forth in the Company’s most recent Form 10-K, Form 10-Q and other filings with the
Securities and Exchange Commission (SEC). Investors are urged to review the Company’s SEC filings. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Companyassumes no obligation and does not intend to update these forward-looking statements or to conform these statementsto actual results or to changes in the Company's expectations.
Forward-Looking Statements
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
3/38
3
3
NASDAQ: IVTY
Philip Sawyer, Chief Executive Officer Jim Mackaness, Chief Financial Officer
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
4/38
4
4
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
5/38
5
5
of all surgical procedures are openminimally invasive and minimal access*
* Based on company estimate for the U.S.5
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
6/38
6
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
7/38
7
Proprietary Intelligent Photonics™ Technology
~ 2.0B US Market
162,000 Procedures
>61% YoY Revenue Growth 2015 vs. 2014
Platform Technology--9 Product Families
Company Snapshot*
~80% of Revenue from Single–Use Devices
~
* As of March 31, 2016
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
8/38
88
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
9/38
99
overheadlights
fiberoptics
headlights
9
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
10/38
10
POORVISUALIZATION
10
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
11/38
1111
IntelligentPhotonics ™
Technology03.REFRACTIVEMICROSTRUCTURES
04.THERMALLY COOLILLUMINATION
01.SOLID COREOPTICAL POLYMER
02.TOTAL INTERNALREFLECTION AND LIGHTMIXING
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
12/38
1212
01. SOLID COREOPTICAL POLYMER
Efficient transmission oflight
Less heatbuildup
Efficient coupling
01.SOLID COREOPTICAL POLYMER
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
13/38
1313
02. TOTAL INTERNALREFLECTION
AND LIGHT MIXING
Efficient transmission oflight prior to extraction
02.TOTAL INTERNALREFLECTION AND LIGHTMIXING
Light mixing reducesglare and bright spots
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
14/38
1414
03. REFRACTIVEMICROSTRUCTURES
Off-axis lightextraction
Broad, uniform,volumetricillumination
Reducedshadows andglare
03.REFRACTIVEMICROSTRUCTURES
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
15/38
15
TEMPERATURE (C˚)
50.3 °CmaximumAt 44˚C and above a
burn can occur
15
IntelligentPhotonics™Technology
TraditionalFiber Optic
33.2 °Cmaximum
* Per co. bench testing
*
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
16/38
16
LIGHT PROJECTION
IntelligentPhotonics™Technology
TraditionalFiber Optic
16* Per co. bench testing
*
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
17/38
17 1717 RetractorDrop-in Handheld
Saber
Yankauer™
Saber
Frazier™
XT
System™ Eikon™
Eika™ Eivector™ Breiten™ Eipex™ Eiberg™
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
18/38
18
/ /
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
19/38
1919
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
20/38
20
*Company estimate
Initial US Beachhead Specialties TAM $1.1B
2B US Total Available Market
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
21/38
21
TRAUMA/TUMOR(Ortho)
LUMBAR(Spine)
SHOULDER(Ortho)
BREASTONCOLOGY
HIP (Ortho)
CERVICAL (Spine)
BREASTRECONSTRUCTION
Other Specialties
21
Specialties
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
22/38
22
Breast Oncology and Reconstruction Opportunity
Key Procedure Targets
• Nipple Sparing Mastectomy
• Skin Sparing Mastectomy• Breast Reconstruction• Lumpectomy
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
23/38
23
Superior Visualization During...Nipple Sparing Mastectomy
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
24/38
24
92
…report Eikon improves patient safety
100
9292 …report Eikon reduces heat and thermalhazards in operating room
…report Eikon improves surgical efficiency
in performing NSMs
…report that Eikon reduces procedure
time for NSMs. Approximately 36 minutesOR time saved
Breast Surgeon Survey Results*
* Survey of 12 breast oncology surgeon thought leaders24
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
25/38
252525
RETROSPECTIVE CHART REVIEW OF NIPPLE SPARING MASTECTOMIES WITH AND WITHOUT AENABLING INTRACAVITY ILLUMINATION AND VISUALIZATION SYSTEM
Authors : Beth Baughman DuPree MD, FACS, ABIHM, William Scarlett DO, FACS, FACOS, FAACS,Anna Smaron, Marie Cassese, Darren Eskow, and Jeff Gross
ffili tions : Adjunct Assistant Professor of Surgery University of Pennsylvania, Philadelphia PA,Chairman Department of Surgery Holy Redeemer Hospital, Medical Director Integrative MedicineHoly Redeemer Health System, Meadowbrook, PA Associate Professor of Plastics Surgery,PCOM, Philadelphia PA, Medical Director of Bucks County Aesthetic Center, Bensalem, PA
Procedure: Unilateral and Bilateral Nipple Sparing MastectomyResults:*Average of 31 min. reduction in anesthesia time in bilateral NSM20% increase in procedures among patients with C and D cup size100% decrease in compromised flaps in combined unilateral/bilateral surgeries**70% decrease in epidermolysis in combined unilateral/bilateral surgeries**_____________________________________________________________________________
Total potential savings of 580 to 2000 per procedure using Invuity devices***
* Results reflect changes after surgeon adoption of Invuity’s Eikon illuminated retractor system** Due to introduction of Invuity's Eikon Illuminated retractor system and potentially the advanced electrosurgical device*** Study and economic analysis performed by leading outside healthcare consulting firm
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
26/38
262626
• Surgeon Certification and Training Program onOncoplastic Techniques
• Women’s Health Focus—Breast, Thyroid,Gynecology
• Center of Excellence Certification and Designation
Online
• Hidden Scar™ Centers ofExcellence Finder atBreastCancerSurgery.com
• Hidden Scar™ Certified SurgeonFinder atBreastCancerSurgery.com
• My Hidden Scar Microsite atMyHiddenScar.com
• Social media (Facebook, Twitter,Pinterest)
External Marketing
• Radio Spots• Print Ads• Billboard Ads• Media Relations/PR
• Newsletter Templates• Website templates• Patient Education Presentation• Referral Letters
Internal Marketing
• On-hold message• Waiting Room Patient Education
Video• Lobby/Waiting Room Displays and
Wall Posters• Patient Education Brochures
mailto:www.breastcancersurgery.commailto:www.breastcancersurgery.commailto:www.myhiddenscar.commailto:www.myhiddenscar.commailto:www.breastcancersurgery.commailto:www.breastcancersurgery.com
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
27/38
272727
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
28/38
Orthopedics
Saber Frazier™ Saber Yankauer™
Eiberg™
Eipex™Eivector™
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
29/38
29
Key Procedure Targets
MIS Anterior Hip Arthroplasty Shoulder Arthroplasty
Foot and Ankle Hip Revisions Trauma
Orthopedics Opportunity
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
30/38
303030
Anterior Hip Arthroplasty—Visualization of the Femoral Canal
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
31/38
313131
Spine Opportunity
Key Procedure Targets
Posterior lumbar decompression Posterior lumbar fusion Anterior lumbar fusion
Anterior and posterior cervicaldecompression
Anterior cervical fusion
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
32/38
323232
Saber Frazier™ in Posterior Lumbar Fusion
Superior visualization. Ability to achieve rapid hemostasis.
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
33/38
33
Expand “deeper” to new surgicalprocedures and specialties—top/down strategy
~162,000 procedures
performed to date vs. ~92,000as of Q1 2015
Expanding US sales organization
Customer account growth—545accounts Q1 2016 vs. 410 Q12015
CommercializationStrategy
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
34/38
34
Financial Overview
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
35/38
35
Topline Growth Year Over Year
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
36/38
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
37/38
37
Experienced Management Team
Large Under-Penetrated Market
Significant Clinical & Product Advantageswith Strong IP
Favorable Economics
Investment Summary
8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016
38/38
38